Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)[1] and OXB,[2] today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

PDA has released Points to Consider No. 11 Development, Classification, Manufacture, Control, and Testing of Plasmids and Vectors Used in ATMP Production on its bookstore and membership technical ...